David Standaert News Today

Lixisenatide, a drug in the same family as Ozempic, seems to slow the progression of Parkinson’s disease. Plus, why scientists will look to the Sun’s corona during the 8 April eclipse. Lixisenatide, a drug in the same family as Ozempic, seems to slow the progression of Parkinson’s disease. Plus, why scientists will look to the Sun’s corona during the 8 April eclipse.

Diabetes drug lixisenatide could slow down progression of Parkinsons disease, a development thats considered a significance step in the diseases management. | Health

The booming class of GLP-1 drugs that includes Ozempic and Wegovy are showing potential to help conditions involving the brain.

The drug, which is in the same family as blockbuster weight-loss drugs such as Wegovy, slowed development of symptoms by a small but statistically significant amount. The drug, which is in the same family as blockbuster weight-loss drugs such as Wegovy, slowed development of symptoms by a small but statistically significant amount.

Phase II study of GLP-1 drug lixisenatide meets primary endpoint

Promising, Rising-Star Researchers, Clinicians, and Advocates from around the World Present New Study Findings in Parkinson’s Disease

/PRNewswire/ -- Coave Therapeutics (Coave), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central...

/PRNewswire/ -- Appello Pharmaceuticals, Inc., a clinical-stage pharmaceutical company committed to addressing the needs of people suffering from disorders of...